友芝友生物(02496.HK)M701治疗恶性腹水新药上市申请获受理

阿斯达克财经
May 07

友芝友生物-B(02496.HK) 公布,自主研发的双特异性抗体药物M701治疗晚期上皮性恶性肿瘤导致的恶性腹水的新药上市申请已获得国家药监局正式受理。M701正在中国开展针对恶性腹水及恶性胸水的多项不同阶段的临床试验,包括一项针对上皮性实体瘤引发的恶性腹水的关键III期临床试验,其新药上市申请已获国家药监局的正式受理,以及一项针对非小细胞肺癌引发的恶性胸水的II期临床试验,目前已完成受试者入组。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10